SLS Stock Analysis: Buy, Sell, or Hold?
SLS - SELLAS Life Sciences Group, Inc. Common Stock
$12.40
-0.79 (-6.03%)
▼
5d:
-1.78%
30d:
+59.73%
90d:
+137.45%
BUY
MODERATE Confidence
Analysis Updated: Jul 20, 2026 12:00 AM ET
Earnings: Aug 11, 2026
21d
Smart Money Accumulation
None View Scanner →
Strength: 10.0/10
Get Alerted When SLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SLS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SLS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SLS is currently trading at $12.39, which is considered fair relative to its 30-day fair value range of $8.86 to $14.09.
Technical Outlook: Technically, SLS is in a strong uptrend. Immediate support is located at $11.40, while resistance sits at $14.99. Short-term momentum is weak, with the stock down 6.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $27.50 (+108.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SLS is in a strong uptrend. Immediate support is located at $11.40, while resistance sits at $14.99. Short-term momentum is weak, with the stock down 6.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $27.50 (+108.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.86 -
$14.09
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.0%)
- BULLISH: Trading 108.5% below Wall St target ($27.50)
Trading Range Analysis
30-Day Trading Range
$8.86 -
$14.09
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$11.40
Resistance Level
$14.99
Current Trend
Strong Uptrend
Technical data as of
Jul 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-105.52
Wall Street Target
$27.50
(+108.5%)
Revenue Growth (YoY)
-82.5%
Share & Embed Analysis
Last updated: July 20, 2026 2:05 PM ET
Data refreshes hourly during market hours. Next update: 3:05 PM
Data refreshes hourly during market hours. Next update: 3:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 62 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$280 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 53 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$114 | 56 HOLD |
Advanced SLS Option Strategies
Professional options setups generated by AI based on today's SLS price and gamma walls.
